3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors protect against oxidized low-density lipoprotein-induced endothelial dysfunction

Endothelium: Journal of Endothelial Cell Research

Volumn 10, Issue 1, 2003, Pages 17-21

  Li, Dayuan ^a,b   Mehta, Jawahar L ^a,b  

^a UNIVERSITY OF ARKANSAS AT LITTLE ROCK   (United States)

^b CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

Author keywords

Atherosclerosis; Endothelial dysfunction; Oxidized LDL; Statins

Indexed keywords

ATORVASTATIN; FREE RADICAL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; NITRIC OXIDE SYNTHASE; OXIDIZED LOW DENSITY LIPOPROTEIN; PRAVASTATIN; SIMVASTATIN;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CELL ADHESION; CIGARETTE SMOKING; CLINICAL TRIAL; DIABETES MELLITUS; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; ENDOTHELIUM CELL; ENDOTHELIUM INJURY; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION; HEART PROTECTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MONOCYTE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIDE EFFECT; THROMBOCYTE AGGREGATION;

ANIMALS; ARTERIOSCLEROSIS; ENDOTHELIUM; FREE RADICALS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPOPROTEINS, LDL; NITRIC OXIDE SYNTHASE; OXIDATIVE STRESS;

EID: 0037230876     PISSN: 10623329     EISSN: None     Source Type: Journal    
DOI: 10.1080/10623320303355     Document Type: Review

References (46)

1. Alfon J., Guasch J.F., Berrozpe M., and Badimon L. (1999) Nitric oxide synthase II (NOS II) gene expression correlates with atherosclerotic intimal thickening. Preventive effects of HMG-CoA reductase inhibitors. Atherosclerosis, 145, 325-331.
2. Amberger A., Maczek C., Jurgens G., Michaelis D., Schett G., Trieb K., Eberl T., Jindal S., Xu Q., and Wick G. (1997) Co-expression of ICAM-1, VCAM-1, ELAM-1 and HSP60 in human arterial and venous endothelial cells in response to cytokines and oxidized low-density lipoproteins. Cell Stress and Chaperones, 2, 94-103.
3. Bickel P.E., and Freeman M.W. (1992) Rabbit aortic smooth muscle cells express inducible macrophage scavenger receptor messenger RNA that is absent from endothelial cells. Journal of Clinical Investigation, 90, 1450-1457.
4. Crisby M., Nordin-Fredriksson G., Shah P.K., Yano J., Zhu J., and Nilssonn J. (2001) Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: Implications for plaque stabilization. Circulation, 103, 926-933.
5. Drake T.A., Hanani K., Fei H.H., Lavi S., and Berliner J.A. (1991) Minimally oxidized low density lipoprotein induces tissue factor expression in cultured human endothelial cells. American Journal of Pathology, 138, 601-607.
6. Erl W., Weber P.C., and Weber C. (1998) Monocytic cell adhesion to endothelial cells stimulated by oxidized low-density lipoprotein is mediated by distinct endothelial ligands. Atherosclerosis, 136, 297-303.
7. Eto M., Kozai T., Cosentino F., Joch H., and Luscher T.F. (2002) Statin prevents tissue factor expression in human endothelial cells: Role of Rho/Rho-kinase and Akt pathways. Circulation, 105, 1756-1759.
8. Gerrity R.G. (1981) The role of the monocyte in atherogenesis, I: Transition of blood borne monocytes into foam cells in fatty lesions. American Journal of Pathology, 103, 181-190.
9. Girona J., La Ville A.E., Sola R., Plana N., and Masana L. (1999) Simvastatin decreases aldehyde production derived from lipoprotein oxidation. American Journal of Cardiology, 83, 846-851.
10. Hernandez-Perera O., Perez-Sala D., Navarro-Antolin J., Sanchez-Pascuala R., Hernandez G., Diaz C., and Lamas S. (1998) Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. Journal of Clinical Investigation, 101, 2711-2719.
11. Iwai-Kanai E., Hasegawa K., Sawamura T., Fujita M., Yanazume T., Toyokumi S., Adachi S., Kihara Y., and Sasayama S. (2001) Activation of lectin-like oxidized low-density lipoprotein receptor-1 induces apoptosis in cultured neonatal rat cardiac myocytes. Circulation, 104, 2948-2954.
12. Jialal I., and Devaraj S. (1996) The role of ox-LDL in atherogenesis. Journal of Nutrition, 126, 1053S-1057S.
13. Kanaider N.C., Egger P., Dunzendorfer S., Noris P., Balduini C.L, Gritti D., Ricevuti G., and Widermann C.J. (2002) Reversal of thrombin-induced deactivation of CD39/ATPDase in endothelial cells by HMG-CoA reductase inhibition: Effects on Rho-GTPase and adenosine nucleotide metabolism. Arteriosclerosis, Thrombosis, and Vascular Biology, 2, 894-900.
14. Keaney J.F. Jr., Guo Y., Cunningham D., Shwaery G.T., Xu A., and Vita J.A. (1996) Vascular incorporation of alpha-tocopherol prevents endothelial dysfunction due to oxidized LDL by inhibiting protein kinase C stimulation. Journal of Clinical Investigation, 98, 386-394.
15. Keidar S., and Attias J. (1997) Angiotensin II injection into mice increases the uptake of oxidized LDL by their macrophages via a proteoglycan-mediated pathway. Biochemical and Biophysical Research Communications, 239, 63-67.
16. Kugiyama K., Kerns S.A., Morrisett J.D., Roberts R., and Henry P.D. (1990) Impairment of endothelium dependent arterial relaxation by lysolecithin in modified low density lipoproteins. Nature, 344, 160-162.
17. Kume N., Murase T., Moriwaki H., Aoyama T., Sawamura T., Masaki T., and Kita T. (1998) Inducible expression of lectin-like oxidized LDL receptor-1 in vascular endothelial cells. Circulation Research, 83, 322-327.
18. Kureishi Y., Luo Z., Shiojima I., Bialik A., Fulton D., Lefer D.J., Sessa W.C., and Walsh K. (2000) The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nature Medicine, 6, 1004-1010.
19. Li D.Y., Chen H.J., and Mehta J.L. (2001) Statins inhibit oxidized-LDL-mediated LOX-1 expression, uptake of oxidized-LDL and reduction in PKB phosphorylation. Cardiovascular Research, 52, 130-135.
20. Li D.Y., Chen H.J., Romeo F., Saldeen T., and Mehta J.L. (2002) Statins modulate ox-LDL-mediated adhesion molecule expression in human coronary artery endothelial cells: Role of LOX-1. Journal of Pharmacology and Experimental Therapeutics, 302, 1-5.
21. Li D.Y., and Mehta J.L. (2000a) Antisense to LOX-1 inhibits oxidized LDL-mediated upregulation of monocyte chemoattractant protein-1 and monocyte adhesion to human coronary artery endothelial cells. Circulation, 101, 2889-2895.
22. Li D.Y. and Mehta J.L. (2000b) Upregulation of endothelial receptor for oxidized LDL (LOX-1) by oxidized LDL and implications in apoptosis of human coronary artery endothelial cells: Evidence from use of antisense LOX-1 mRNA and chemical inhibitors. Arteriosclerosis, Thrombosis, and Vascular Biology, 20, 1116-1122.
23. Li D.Y., Saldeen T., and Mehta J.L. (1999) Gamma-tocopherol decreases ox-LDL-mediated activation of nuclear factor-κB and apoptosis in human coronary artery endothelial cells. Biochemical and Biophysical Research Communications, 259, 157-161.
24. Li D.Y., Tomson K., Yang B.C., and Mehta P., Croker B.P., and Mehta J.L. (1999) Modulation of constitutive nitric oxide synthase, Bcl-2 and Fas expression in cultured human coronary endothelial cells exposed to anoxia-reoxygenation and angiotensin II: Role of AT1 receptor activation. Cardiovascular Research, 41, 109-115.
25. Li D.Y., Williams V., Liu L., Chen H.J., Sawamura T., Antakli T., and Mehta J.L. (2002) LOX-1 inhibition in myocardial ischemia-reperfusion injury: Modulation of MMP-1 and inflammation. American Journal of Physiology, 283, H1795-H1801.
26. Li D.Y., Yang B.C., and Mehta J.L. (1999) Ox-LDL induces apoptosis in human coronary artery endothelial cells: Role of PKC, PTK, bcl-2, and Fas. American Journal of Physiology, 275, H568-H576.
27. Li D.Y., Zhang Y.C., Philips M.J., Sawamura, T., and Mehta J.L. (1999) Upregulation of endothelial receptor for oxidized low-density lipoprotein (LOX-1) in cultured human coronary artery endothelial cells by angiotensin II type 1 receptor activation. Circulation Research, 84, 1043-1049.
28. Luscher T.F., Tanner F.C., and Noll G. (1996) Lipids and endothelial function: Effects of lipid lowering and other therapeutic interventions. Current Opinion in Lipidology, 7, 234-240.
29. Metha A., Yang B., Khan S., Hendricks J.B., Stephen C., and Mehta J.L. Oxidized low-density lipoproteins facilitate leukocyte adhesion to aortic intima without affecting endothelium-dependent relaxation. Role of P-selectin. Arteriosclerosis, Thrombosis, and Vascular Biology, 15, 2076-2083.
30. Mehta J.L., and Li D.Y. (1998) Identification and autoregulation of receptor for ox-LDL in cultured human coronary artery endothelial cells. Biochemical and Biophysical Research Communications, 248, 511-514.
31. Mehta J.L., and Li D.Y. (2002) Identification, regulation and function of LOX-1, a novel receptor for ox-LDL. Journal of American College of Cardiology, 39, 1429-1435.
32. Mehta J.L., Li D.Y., Chen H.J., Joseph J., and Romeo F. (2001) Inhibition of LOX-1 by statins may relate to upregulation of eNOS. Biochemical and Biophysical Research Communications, 289, 857-861.
33. Niwa S., Totsuka T., and Hayashi S. (1996) Inhibitory effect of fluvastatin, an HMG-CoA reductase inhibitor, on the expression of adhesion molecules on human monocyte cell line. International Journal of Immunopharmacology, 18, 669-675.
34. Rahman M.M., Varghese Z., Fuller B.J., and Moorhead J.F. (1999) Renal vasoconstriction induced by oxidized LDL is inhibited by scavengers of reactive oxygen species. Clinical Nephrology, 51, 98-107.
35. Rezaie-Majd A., Maca T., Bucek R.A., Valent P., Muller M.R., Husslein P., Kashanipour A., Minar E., and Baghestanian M. (2002) Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arteriosclerosis, Thrombosis, and Vascular Biology, 22, 1194-1199.
36. Ridker P.M., Rifai N., Clearfield M., Downs J.R., Weis SE., Miles J.S., and Gotto A.M. Jr. (2001) Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. New England Journal of Medicine, 344, 1959-1965.
37. Ross R. (1999) Atherosclerosis - An inflammatory disease. New England Journal of Medicine, 340, 115-126.
38. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G.,Brown L., Warnica J.W., Arnold J.M., Wun C.C., Davis B.R., and Braunwald E. (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. New England Journal of Medicine, 335, 1001-1009.
39. Scandinavian Simvastatin Survival Study Group. (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet, 344, 1383-1389.
40. Skaletz-Rorowski A., Muller J.G., Kroke A., Waltenberger J., Pulawski E., Pinkernell K., and Breithardt G. (2001) Lovastatin blocks basic fibroblast growth factor-induced mitogen-activated protein kinase signaling in coronary smooth muscle cells via phosphatase inhibition. European Journal of Cell Biology, 80, 207-212.
41. The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. (1998) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. New England Journal of Medicine, 339, 1349-1357.
42. Tsutsui T., Tsumato T., Wada A., Maeda K., Mabuchi N., Hayashi M., Ohnishi M., and Kinoshita M. (2002) Plasma oxidized low-density lipoprotein as a prognostic predictor in patients with chronic congestive heart failure. Journal of American College of Cardiology, 39, 957-962.
43. Waters D., Higginson L., Gladstone P., Kimball B., Le May M., Boccuzzi S.J., and Lesperance J. (1994) Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial. Circulation, 89, 959-968.
44. Weitz-Schmidt G., Welzenbach K., Brinkmann V., Kamata T., Kallen J., Bruns C., Cottens S., Takada Y., and Hommel U. (2001) Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nature Medicine, 7, 687-692.
45. Witztum J.L., and Steinberg D. (1991) Role of oxidized low-density lipoprotein in atherogenesis. Journal of Clinical Investigation, 88, 1785-1792.
46. Zhou Y.F., Guetta E., Yu Z.X., Finkel T., and Epstein S.E. (1996) Human cytomegalovirus increases modified low-density lipoprotein uptake and scavenger receptor mRNA expression in vascular smooth muscle cells. Journal of Clinical Investigation, 98, 2129-2138.